A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
The aim of this study is to compare the safety and efficacy of SHR3680 with bicalutamide in
the treatment of patients with hormone sensitive prostate cancer.